secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001493152-25-018267
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity receives US patent allowance for AI-driven lung cancer diagnostic
-----------------------------------------------------------------------------

- USPTO allowed patent covering AI-built algorithm and flow cytometry platform for CyPath Lung test.
- Patent titled 'Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning'.
- CyPath Lung uses TCPP porphyrin and AI to detect lung cancer in sputum; clinical results: 92% sensitivity, 87% specificity, 88% accuracy.
- Global patent estate now includes 18 awarded and 33 pending patents across 12 countries.
- Diagnostic aims to detect early-stage lung cancer (Stage 1A) noninvasively, potentially curative.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225018267/0001493152-25-018267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225018267/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer